Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153124 | 0.79 | APP (0.42) | APPCYP19A1HSD17B1HSD17B2CA1 | |
| SCHEMBL6832420 | 0.75 | APP (0.42) | APPCYP19A1HSD17B1HSD17B2CA1 | |
| SCHEMBL467307 | 0.74 | APP (0.47) | APPCYP19A1HSD17B1HSD17B2CA1 | |
| SCHEMBL4324936 | 0.73 | APP (0.44) | APPCYP19A1HSD17B1HSD17B2CA1 | |
| SCHEMBL845603 | 0.73 | APP (0.63) | APPCYP19A1HSD17B1HSD17B2CA1 | |
| SCHEMBL29732980 | 0.73 | APP (0.63) | APPCYP19A1HSD17B1HSD17B2CA1 | |
| SCHEMBL6642970 | 0.70 | RAB9A (0.51) | APPCYP19A1 | |
| SCHEMBL2149612 | 0.69 | APP (0.59) | APPCYP19A1HSD17B1HSD17B2CA1 | |
| SCHEMBL2581028 | 0.69 | CYP19A1 (0.64) | APPCYP19A1HSD17B1HSD17B2CA1 | |
| SCHEMBL15798416 | 0.69 | APP (0.46) | APPCYP19A1HSD17B1HSD17B2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573499-B | 9, 9-Dicarbazole derivative, preparation method thereof and application thereof in luminescence | 维思普新材料（苏州）有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117736218-A | Spirocyclic carbonyl nitrogen compound, polymer, mixture and application thereof | 苏州大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-113233988-B | Fluorene derivative and electronic device | 苏州久显新材料有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-1539151-B1 | BIARYL COMPOUNDS HAVING ANTI-INFECTIVE ACTIVITY | GENESOFT PHARMACEUTICALS INC (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2029570-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-04 | — | — | EP | disclosed |
| US-7498349-B2 | Biaryl compounds having anti-infective activity | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
| EP-1539151-A4 | BIARYL COMPOUNDS HAVING ANTI-INFECTIVE ACTIVITY | GENESOFT PHARMACEUTICALS INC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20060128747-A1 | Biaryl compounds having anti-infective activity | GENESOFT PHARMACEUTICALS,INC. (US) | 2006-06-15 | — | — | US | disclosed |
| EP-1539151-A1 | BIARYL COMPOUNDS HAVING ANTI-INFECTIVE ACTIVITY | Genesoft Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004012736-A1 | BIARYL COMPOUNDS HAVING ANTI-INFECTIVE ACTIVITY | GENESOFT PHARMACEUTICALS, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20030235632-A1 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, LLC (US) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030235632-A1 | Anti-first-pass effect compounds | ABCG2, FABP2, HDLBP | APP 2904/4885CYP19A1 1431/4885HSD17B1 1328/4885 |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | APP 3011/4885CYP19A1 2478/4885HSD17B1 3274/4885 |
| US-20060128747-A1 | Biaryl compounds having anti-infective activity | LSS, BET1, TYR | APP 4607/4885CYP19A1 2286/4885HSD17B1 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.